Cleaning Things Up 2023 was obviously a significant year of change ...and not all of it good as the sp stumbled significantly. But in review and looking forward what can be gleaned from the bold moves that have taken place of late?
* Remove the CEO ....we'll never know exactly why but clearly a change at the top was required
* Cutting and streamlining to improve the bottom line ...this included getting rid of DMEVS and changing direction for the technology behind Nexalogy ...both $ anchors.
* Renewing and gaining new contracts within a narrower perspective ....now in the $millions.
* Setting up the RSUs which should represent a change in remuneration (less $'s directed toward compensation) while limiting dilution relative to the no. of outstanding shares.
Do we actually know the burn rate with all that has gone on of late? What will the expansion of medical offerings, especially in the field of mental health, do for the bottom line of the clinics? How quickly can the diversification into new opportunities for DMs' technology be realized?
Most of the changes appear to be positive ...at this stage management has a responsibility but also deserves an opportunity to demonstrate that the changes are growth and revenue positive.